Familial Primary Pulmonary Hypertension
Common symptoms of the reduced blood flow are passing out, shortness of breath with exercise, and swelling of the ankles and legs. PPH can develop in men or women at any age, but is most common in women in their 20's or 30's. This disease often requires a long time until dia
The Research
NIH Grant PO1 HL072058-01A1 “Genetic and Environmental Pathogenesis of PPH”
The National Institutes of Health are funding a Program Project Grant (through 2008) for a five-year study including a registry of families with FPPH at
The major goals of the study are to find the gene(s) that causes PPH, identify possible modifier genes and/or environmental influences on disease incidence and severity, understand the function of these genes in causing disease, work toward understanding the effects of clinical genetic counseling and testing, and be a resource of information for patients and physicians.
The research is being conducted in collaboration with linkage geneticists at
The Faculty and Staff:
Vanderbilt
James E. Loyd, MD, Principal Investigator
John A. Phillips,
John H. Newman, MD, Project 1, Co-investigator
Ellen Wright-Clayton, MD, JD, Co-investigator
Ivan Robbins, MD, Co-investigator
Lisa Wheeler,
Kirk Lane
Joy Cogan, Ph. D., Director, PPH Genetics Laboratory
Lora Hedges
Krista Stanton
Cindy Vnencak-Jones, Ph.D., Director, Clinical Molecular Genetics Laboratory
Vickie Hannig, MS, Clinical Genetics Counselor
Tatiana Foroud, PhD (need a title)
Daniel Koller, PhD (Title)
William Nichols, PhD
Michael Pauciulo
William Tuchfarber
General Information About the PPH Family Registry
The incidence of PPH in the general population is about 1-2 per million. A NIH study of nearly 200 patients conducted at 30 US medical centers in the 1980's showed that only 6% of these patients had a family history of PPH. Symptoms, clinical course, and response to therapy of FPPH patients is similar to general PPH. The disease can be inherited from a male or female parent. The incidence is 2:1 females to males, similar to the general PPH population. FPPH is inherited as a dominant trait, although, many persons who carry the gene do not get the disease. A gene that causes FPPH has been identified, bone morphogenetic protein receptor 2 (BMPR2). This gene is associated with cell growth and development. "Mistakes" or mutations of this gene may lead to the formation of abnormal pulmonary blood vessel seen in this disease. Over eighty families are currently enrolled in the study. We are actively enrolling new families and expect to do so at least through 2008.
For more information contact:
NATIONAL REGISTRY FOR FAMILIAL PRIMARY
PULMONARY HYPERTENSION
James Loyd, M. D., Director
Lisa Wheeler, Coordinator
Vanderbilt University Medical Center
T-1218 Medical Center North
Nashville, TN 37232-2650
1-800-288-0378 FAX 1-615-343-7587
lisa.wheeler@vanderbilt.edu
A frustrating problem for many patients with pulmonary hypertension is the lack of information and literature that explains the problems and possible treatments. The Pulmonary Hypertension Association (PHA) is an organization of patients and family members, whose mission is to provide family support, education, and patient advocacy. For more information on how to contact PHA see below.
Pulmonary Hypertension Association (PHA):
PHA is primarily a volunteer support group for patients with pulmonary hypertension (PH) of any cause. The group is administered by PH patients and their families. They provide education for patients and physicians about the disease. They also have a nationwide system of support groups and maintain a listing of physicians experienced with treating PPH.
Pulmonary Hypertension Association
850 Sligo Avenue, Suite 800
Silver Spring, MD 20910
1-800-748-7274
www.phassociation.org
PHA publishes a quarterly newsletter, The PATHLIGHT and PERSISTENT VOICES, which is a collection of patients' personal stories.
References
Runo JR, Loyd JE.Primary pulmonary hypertension.
Lancet. 2003 May 3;361(9368):1533-44.
Runo JR, Vnencak_Jones CL, Prince M, Loyd JE, Wheeler L, Robbins IM, Lane KB, Newman JH, Johnson J, Nichols WC, Phillips JA 3rd.
Pulmonary veno_occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II.
Am J Respir Crit Care Med. 2003 Mar 15;167(6):889-94.
Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM.
Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol.
Am J Respir Crit Care Med. 2003 Feb 15;167(4):580-6.
Newman, J.H., Wheeler, L., Lane, K.B., Loyd, E., Gaddipati, R., Phillips, J.A. III, Loyd, J.E.
Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.
N. Engl. J. Med. 345:319-24, 2001.
Lane, K.B., Machado, R.D., Pauciulo, M.W., Thompson, J.R., Philips, J.A. III, Loyd, J.E., Nichols, W.C., Trembath, R.C.
Heterozygous germline mutations in a TGF-beta receptor, BMPR2, are the cause of familial primary pulmonary hypertension.
Nature Genetics. 2626(1):81-84, 2000.